Targeted therapy before surgery for HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) given as a shot under the skin before surgery for women with a specific type of breast cancer called HER2-positive. The goal is to see if this treatment works well for women in Algeria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 19 or older.
- Your breast cancer is HER2-positive (a specific type that grows fast) and has not spread to distant organs.
- You are able to start treatment before surgery (neoadjuvant therapy) as decided by your doctor.
- Your heart function is normal (LVEF of 50% or more).
- You have not had prior treatment with trastuzumab or pertuzumab, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
Hear when a new Non Metastatic HER2 Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.